A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial.

Plain-language guide to PMID 28673363 (2017): double-blind randomized controlled trial of Copper (Supplement) in 50 patients.

Key Facts

PMID: 28673363
Journal: Trials
Year: 2017
Study type: Randomized Controlled Trial
Authors: Hermans N et al. (8 authors)
DOI: 10.1186/s13063-017-2058-5
Registered trial: NCT02065180

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Metabolic syndrome (MetS) refers to clustered cardiovascular risk factors (abdominal obesity, pre-diabetes, high blood pressure, dyslipidaemia).

Therapies targeting oxidative stress may delay progression to atherosclerosis and diabetes.

Who Took Part

The abstract describes 50 patients taking part.

PubMed tags the participants as both men and women.

A double-blind, placebo-controlled, randomised trial was conducted with 50 patients with MetS as defined by National Cholesterol Education Program Adult Treatment Panel III criteria.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Copper (Supplement).

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

Statistical calculations included univariate quantitative analysis, multivariate linear regression and correlation analysis.

What Was Measured

Topics PubMed links to this paper include 1-Alkyl-2-acetylglycerophosphocholine Esterase, 8-Hydroxy-2'-Deoxyguanosine, Antioxidants, Belgium, Biological Products, Biomarkers and Deoxyguanosine.

Author keywords: Metabolic syndrome, Olive, Oxidative stress and Red yeast rice.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 50 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Trials), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Copper (Supplement) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.